<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318836</url>
  </required_header>
  <id_info>
    <org_study_id>USWM-LX1-1007</org_study_id>
    <secondary_id>1R01DA030916</secondary_id>
    <nct_id>NCT02318836</nct_id>
  </id_info>
  <brief_title>Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects</brief_title>
  <official_title>Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>US WorldMeds LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult&#xD;
      subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with&#xD;
      moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic&#xD;
      impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with&#xD;
      mean age, body mass index (BMI), and gender distribution targeted to be similar to the&#xD;
      impaired hepatic function cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult&#xD;
      subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with&#xD;
      moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic&#xD;
      impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with&#xD;
      mean age, body mass index (BMI), and gender distribution targeted to be similar to the&#xD;
      impaired hepatic function cohorts. Subjects will be confined to an inpatient facility from&#xD;
      the evening before dosing to 144 hours after dosing.&#xD;
&#xD;
      Subjects who successfully complete screening will report to the inpatient facility at an&#xD;
      appropriate time the evening before study drug administration (Day 1) to ensure a minimum 10&#xD;
      hour fast. The next morning (Day 1) while still fasting, subjects will receive a single, oral&#xD;
      dose of 400 µg lofexidine HCl (two 200 µg tablets). Blood samples will be collected for&#xD;
      pharmacokinetic (PK) analysis at multiple time points over the next 144 hours (Day 7). Pooled&#xD;
      urine samples will be collected at 0 3 hours, 3 6 hours, 6 12 hours, 12 24 hours, 24 48&#xD;
      hours, 48 96 hours, 96 120 hours and 120 144 hours post-dose. Safety will be assessed by&#xD;
      recording adverse events (AEs), measuring vital signs (blood pressure and pulse rate) and&#xD;
      clinical laboratory tests (chemistry, hematology, and urinalysis), recording 12 lead safety&#xD;
      and Holter electrocardiograms (ECGs), and performing physical exams.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Profile: Cmax, Tmax, AUC, λz, CL/F, T½, CLr, CLd, Ae</measure>
    <time_frame>pre dose until 144 hours post-dose</time_frame>
    <description>Cmax, Tmax, AUC, λz, CL/F, T½, CLr, CLd, Ae</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>screening through day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>screening through day 7</time_frame>
    <description>hematology, chemistry, urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>screening through day 7</time_frame>
    <description>blood pressure and pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>screening through day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holter ECG</measure>
    <time_frame>pre dose through 8 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Normal Hepatic function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Child-Pugh score 5-6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Child-Pugh score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Child-Pugh score 10-15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine Hydrochloride (HCl) tablets</intervention_name>
    <description>Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic function</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Site will evaluate each subject for criteria in detail, which will include:&#xD;
&#xD;
          1. Between ages of 18 to 65 years at enrollment with a BMI between 19 and 38 kg/m2,&#xD;
             inclusive.&#xD;
&#xD;
          2. Subject is eligible to enter the study if:&#xD;
&#xD;
               -  Matched control subject: normal hepatic function and free from other clinically&#xD;
                  significant illnesses or disease, and medical history, physical examination,&#xD;
                  laboratory results, and other tests consistent with health, as determined by the&#xD;
                  Investigator.&#xD;
&#xD;
               -  Subject with mild hepatic impairment: Child-Pugh hepatic dysfunction staging&#xD;
                  system score of 5-6 Points (Stage A) and medical history, physical examination,&#xD;
                  laboratory results, and other tests consistent with their hepatic impairment, as&#xD;
                  determined by the Investigator.&#xD;
&#xD;
               -  Subject with moderate hepatic impairment: Child-Pugh hepatic dysfunction staging&#xD;
                  system score of 7 9 Points (Stage B) and medical history, physical examination,&#xD;
                  laboratory results, and other tests consistent with their hepatic impairment, as&#xD;
                  determined by the Investigator.&#xD;
&#xD;
               -  Subject with severe hepatic impairment: Child-Pugh hepatic dysfunction staging&#xD;
                  system score of 10-15 Points (Stage C) and medical history, physical examination,&#xD;
                  laboratory results, and other tests consistent with their hepatic impairment, as&#xD;
                  determined by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Site will evaluate each subject for criteria in detail, which will include:&#xD;
&#xD;
          1. The matched control subject has a history of clinically significant disease, including&#xD;
             cardiovascular, gastrointestinal (GI), renal, hepatic, pulmonary, endocrine,&#xD;
             hematologic, vascular, immunologic, metabolic, or collagen disease or the&#xD;
             hepatically-impaired subject has a history of clinically significant disease including&#xD;
             cardiovascular, GI, renal, pulmonary, endocrine, hematologic, vascular, immunologic,&#xD;
             metabolic, or collagen disease.&#xD;
&#xD;
          2. Abnormal cardiovascular exam at Screening, including any of the following:&#xD;
&#xD;
               -  clinically significant abnormal ECG (e.g., second or third degree heart block,&#xD;
                  uncontrolled arrhythmia, QTcF (Fridericia's correction) interval &gt;450 msec for&#xD;
                  males and &gt;470 msec for females).&#xD;
&#xD;
               -  heart rate &lt;45 bpm or symptomatic bradycardia;&#xD;
&#xD;
               -  systolic blood pressure &lt;90 mmHg or symptomatic hypotension;&#xD;
&#xD;
               -  blood pressure &gt;160/100 mmHg; or&#xD;
&#xD;
               -  prior history of myocardial infarction.&#xD;
&#xD;
          3. Subjects with hepatic impairment will not be eligible to participate in the study if&#xD;
             any of the following exclusion criteria also apply:&#xD;
&#xD;
               -  Significant bleeding diathesis or esophageal bleeding within the last 8 weeks.&#xD;
&#xD;
               -  Evidence of hepatic function deterioration within the last 4 weeks as indicated&#xD;
                  by liver transaminases, alkaline phosphatase, and gamma-glutamyl transpeptidase&#xD;
                  or a ≥50% worsening of serum bilirubin or prothrombin time.&#xD;
&#xD;
               -  History of surgical portosystemic shunt.&#xD;
&#xD;
               -  Prothrombin time &gt;18 seconds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Longstreth, PhD</last_name>
    <role>Study Director</role>
    <affiliation>US WorldMeds LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Gorodetzky, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>US WorldMeds LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic, hepatic impairment, lofexidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

